Inhibitor Therapeutics, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a continued focus on research and development without generating any revenue during the periods. The company recorded total expenses of $741,215 for the three months ended September 30, 2025, a decrease from $813,196 in the same period of 2024. For the nine-month period, total expenses were $2,111,539, down from $2,173,160 year-over-year. The net loss for the third quarter was $712,184, slightly improved from a loss of $730,957 in the prior year, while the nine-month net loss increased to $2,004,972 from $1,917,358.
The company's balance sheet as of September 30, 2025, showed total assets of $3,135,167, a significant decline from $5,694,658 at the end of 2024. Cash and cash equivalents decreased to $2,976,658 from $5,606,863, reflecting the company's ongoing investment in its research initiatives. Current liabilities also decreased to $87,533 from $709,618, primarily due to a reduction in accrued expenses. Stockholders' equity fell to $3,453 from $1,985,040, largely driven by the accumulated deficit, which increased to $54,124,229.
In terms of strategic developments, Inhibitor Therapeutics has been actively pursuing its drug development pipeline, particularly focusing on therapies for basal cell carcinoma and other cancers using itraconazole. The company entered into an Exclusive License Agreement with Johns Hopkins University in December 2023, granting it worldwide patent rights for a new angiogenesis inhibitor related to prostate cancer and basal cell carcinoma. The company is also preparing for a pre-investigational new drug application meeting with the FDA to discuss its development plans for itraconazole in treating BCC tumors.
Operationally, Inhibitor Therapeutics has engaged Avior Bio, Inc. to develop a novel formulation of itraconazole, which is expected to undergo a pharmacokinetic crossover study. The company anticipates that this formulation will demonstrate comparable pharmacological properties to those used in previous clinical trials. As of September 30, 2025, the company had 172,573,545 shares of common stock outstanding, reflecting a slight increase from the previous year. The company continues to assess its capital requirements and may seek additional funding to support its operational plans, although it acknowledges the uncertainty surrounding future capital raises.
Looking ahead, Inhibitor Therapeutics aims to leverage its existing cash reserves to manage operations and pursue FDA processes for its BCCNS product without the need for further clinical trials. The company plans to clarify the requirements for its new drug application in the coming months and will evaluate its capital needs accordingly. However, management has cautioned that there are no guarantees regarding the success of its operational plans or the ability to raise additional capital on favorable terms.
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on repurposing approved drugs, particularly itraconazole, for cancer treatment. It targets cancers such as basal cell carcinoma, prostate, and lung cancers by developing Hedgehog pathway inhibitors. The company advances clinical research, secures intellectual property, and seeks FDA designations to expedite approvals, aiming for market exclusivity and strategic partnerships in oncology therapeutics.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.